Generalizability of Landmark Temporary MCS Device Trials: Insights From the CSWG Registry

Area of Science:

• Cardiology
• Clinical Trials
• Medical Devices

Background:

• Landmark trials (DanGer Shock, IABP-SHOCK II, ECLS-SHOCK) inform cardiogenic shock (CS) management using temporary mechanical circulatory support (tMCS).
• Strict trial enrollment criteria may limit the generalizability of findings to real-world patient populations.
• A significant evidence gap exists for CS patients not meeting these specific trial criteria.

Purpose of the Study:

• To assess the overlap between patients in the CS Working Group registry and the eligibility criteria of three key CS trials.
• To compare baseline characteristics and tMCS device utilization between trial-eligible and trial-ineligible CS patients.

Main Methods:

• Retrospective analysis of CS patients from the CS Working Group registry (2020-2024).
• Application of trial-specific enrollment criteria (DanGer Shock, IABP-SHOCK II, ECLS-SHOCK) to registry patients.
• Comparison of demographics, clinical data, and tMCS device usage patterns.

Main Results:

• A small fraction of registry patients met all criteria: 19.3% (DanGer Shock), 28.4% (IABP-SHOCK II), 23.6% (ECLS-SHOCK).
• Hypotension and elevated lactate levels were the most restrictive criteria.
• Trial-eligible patients exhibited more severe CS and end-organ damage.
• Real-world tMCS device use often deviated from trial assignments; only 20% of DanGer-like patients received Impella CP first.

Conclusions:

• Patients meeting landmark CS trial criteria represent a high-risk, minority subset of the real-world CS population.
• A substantial evidence gap exists for the majority of CS patients receiving tMCS in clinical practice.
• Improved registry enrollment and innovative analyses are needed to bridge the gap between trial evidence and real-world application.